246 related articles for article (PubMed ID: 19800002)
1. Regulation of aromatase induction by nuclear receptor coregulator PELP1.
Vadlamudi RK; Rajhans R; Chakravarty D; Nair BC; Nair SS; Evans DB; Chen S; Tekmal RR
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):211-8. PubMed ID: 19800002
[TBL] [Abstract][Full Text] [Related]
2. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
[TBL] [Abstract][Full Text] [Related]
3. Role of PELP1/MNAR signaling in ovarian tumorigenesis.
Dimple C; Nair SS; Rajhans R; Pitcheswara PR; Liu J; Balasenthil S; Le XF; Burow ME; Auersperg N; Tekmal RR; Broaddus RR; Vadlamudi RK
Cancer Res; 2008 Jun; 68(12):4902-9. PubMed ID: 18559538
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Rajhans R; Nair S; Holden AH; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2007 Jun; 67(11):5505-12. PubMed ID: 17545633
[TBL] [Abstract][Full Text] [Related]
5. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.
Chakravarty D; Nair SS; Santhamma B; Nair BC; Wang L; Bandyopadhyay A; Agyin JK; Brann D; Sun LZ; Yeh IT; Lee FY; Tekmal RR; Kumar R; Vadlamudi RK
Cancer Res; 2010 May; 70(10):4092-101. PubMed ID: 20460518
[TBL] [Abstract][Full Text] [Related]
6. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
7. Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.
Nagpal JK; Nair S; Chakravarty D; Rajhans R; Pothana S; Brann DW; Tekmal RR; Vadlamudi RK
Mol Cancer Res; 2008 May; 6(5):851-61. PubMed ID: 18505929
[TBL] [Abstract][Full Text] [Related]
8. PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
Cortez V; Samayoa C; Zamora A; Martinez L; Tekmal RR; Vadlamudi RK
Cancer Res; 2014 Dec; 74(24):7395-405. PubMed ID: 25377474
[TBL] [Abstract][Full Text] [Related]
9. Functional implications of altered subcellular localization of PELP1 in breast cancer cells.
Vadlamudi RK; Manavathi B; Balasenthil S; Nair SS; Yang Z; Sahin AA; Kumar R
Cancer Res; 2005 Sep; 65(17):7724-32. PubMed ID: 16140940
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.
Nair BC; Nair SS; Chakravarty D; Challa R; Manavathi B; Yew PR; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2010 Sep; 70(18):7166-75. PubMed ID: 20807815
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
[TBL] [Abstract][Full Text] [Related]
12. PELP1 oncogenic functions involve alternative splicing via PRMT6.
Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R
Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537
[TBL] [Abstract][Full Text] [Related]
13. Extranuclear coactivator signaling confers insensitivity to tamoxifen.
Kumar R; Zhang H; Holm C; Vadlamudi RK; Landberg G; Rayala SK
Clin Cancer Res; 2009 Jun; 15(12):4123-30. PubMed ID: 19470742
[TBL] [Abstract][Full Text] [Related]
14. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
15. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA; Viswanadhapalli S; Mann M; Chakravarty D; Krishnan S; Liu Z; Liu J; Pratap UP; Ebrahimi B; Sanchez JR; Li X; Ma S; Park BH; Santhamma B; Chen Y; Lai Z; Raj GV; Yuan Y; Zhou D; Sareddy GR; Tekmal RR; McHardy S; Huang TH; Rao MK; Vankayalapati H; Vadlamudi RK
Cancer Res; 2022 Oct; 82(20):3830-3844. PubMed ID: 35950923
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha.
Vadlamudi RK; Wang RA; Mazumdar A; Kim Y; Shin J; Sahin A; Kumar R
J Biol Chem; 2001 Oct; 276(41):38272-9. PubMed ID: 11481323
[TBL] [Abstract][Full Text] [Related]
18. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation.
Manavathi B; Nair SS; Wang RA; Kumar R; Vadlamudi RK
Cancer Res; 2005 Jul; 65(13):5571-7. PubMed ID: 15994929
[TBL] [Abstract][Full Text] [Related]
19. Cloning and functional characterization of PELP1/MNAR promoter.
Mishra SK; Balasenthil S; Nguyen D; Vadlamudi RK
Gene; 2004 Apr; 330():115-22. PubMed ID: 15087130
[TBL] [Abstract][Full Text] [Related]
20. Significance of PELP1 in ER-negative breast cancer metastasis.
Roy S; Chakravarty D; Cortez V; De Mukhopadhyay K; Bandyopadhyay A; Ahn JM; Raj GV; Tekmal RR; Sun L; Vadlamudi RK
Mol Cancer Res; 2012 Jan; 10(1):25-33. PubMed ID: 22086908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
